240 results on '"Marsot, Amélie"'
Search Results
2. Does Sample Size, Sampling Strategy, or Handling of Concentrations Below the Lower Limit of Quantification Matter When Externally Evaluating Population Pharmacokinetic Models?
3. Exposure levels and target attainment of piperacillin/tazobactam in adult patients admitted to the intensive care unit: a prospective observational study
4. Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step
5. Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting
6. Prolonged Beta-Lactam Infusions in Children: A Systematic Review and Meta-Analysis
7. External Evaluation of Population Pharmacokinetic Models for Precision Dosing: Current State and Knowledge Gaps
8. Risk factors associated with augmented renal clearance in a mixed intensive care unit population: a retrospective study
9. Authors’ Reply to Lv et al.: “External Evaluation of Population Pharmacokinetic Models for Precision Dosing: Current State and Knowledge Gaps”
10. Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable?
11. Optimization of Vancomycin Initial Dosing Regimen in Neonates Using an Externally Evaluated Population Pharmacokinetic Model
12. Vancomycin: An analysis and evaluation of eight population pharmacokinetic models for clinical application in general adult population
13. Using a Validated Population Pharmacokinetic Model for Dosing Recommendations of Continuous Infusion Piperacillin for Critically Ill Adult Patients
14. An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients
15. Development and evaluation of a height-based tobramycin initial dosing nomogram for the treatment of adult cystic fibrosis pulmonary exacerbations
16. New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis
17. Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses
18. Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses
19. Nlmixr2 Versus NONMEM: An Evaluation of Maximum A Posteriori Bayesian Estimates Following External Evaluation of Gentamicin and Tobramycin Population Pharmacokinetic Models.
20. Potential benefits of therapeutic drug monitoring for beta-lactam antibiotics in augmented renal clearance patients: a case report
21. Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step
22. An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults
23. Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis
24. β-Lactam Pharmacokinetic/Pharmacodynamic Target Attainment in Intensive Care Unit Patients: A Prospective, Observational, Cohort Study
25. Analytical interference during cefepime therapeutic drug monitoring in intensive care patient: About a case report
26. Comment mesure-t-on le bénéfice net d’un traitement ?
27. How to measure the net benefit of treatment?
28. Development and Evaluation of a Height-Based Tobramycin Initial Dosing Nomogram for the Treatment of Adult Cystic Fibrosis Pulmonary Exacerbations
29. Population pharmacokinetics of methadone hydrochloride after a single intramuscular administration in adult Japanese sika deer (Cervus nippon nippon)
30. Impact of piperacillin unbound fraction variability on dosing recommendations in critically ill patients
31. VANCOmycin dose adjustments comparing trough levels to the ratio of the area under de curve to the minimum inhibitory concentration method using a BAYESian approach: A feasibility study
32. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies
33. Impact of Piperacillin Unbound Fraction Variability on Dosing Recommendations in Critically Ill Patients
34. Model Re-Estimation: An Alternative for Poor Predictive Performance during External Evaluations? Example of Gentamicin in Critically Ill Patients
35. Beta-Lactams in Critically Ill Children: Time to Step Up Our Game?*
36. Validation of the Augmented Renal Clearance in Trauma Intensive Care scoring system for augmented renal clearance prediction in a trauma subgroup of a mixed ICU population
37. PHARMACOKINETICS AND CLINICAL OUTCOMES OF TOBRAMYCIN IN ADULT CYSTIC FIBROSIS PATIENTS WITH ACUTE PULMONARY EXACERBATION
38. Phenobarbital in intensive care unit pediatric population: predictive performances of population pharmacokinetic model
39. New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis.
40. Impact of piperacillin unbound fraction variability on dosing recommendations in critically ill patients.
41. Aminoglycosides’ dosing and monitoring practices in critically ill patients in Quebec hospitals
42. Consideration of height‐based tobramycin dosing regimens for the treatment of adult cystic fibrosis pulmonary exacerbations
43. An Update on Population Pharmacokinetic Analyses of Vancomycin, Part II: In Pediatric Patients
44. Interaction of thiopental with esomeprazole in critically ill patients
45. Population Pharmacokinetic Analysis during the First 2 Years of Life: An Overview
46. Vancomycin: A Review of Population Pharmacokinetic Analyses
47. Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach
48. Population pharmacokinetics of ertapenem in juvenile and old rats
49. High Variability in the Exposure of Baclofen in Alcohol-Dependent Patients
50. Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.